• FDA approves Emmaus' Endari to treat sickle cell disease pharmaceutical-technology
    July 12, 2017
    The US Food and Drug Administration (FDA) has granted approval for Emmaus Life Sciences' Endari (L-glutamine oral powder) to reduce the severe complications of rare, debilitating and lifelong hereditary blood disorder sickle cell disease (SCD) in adult an
PharmaSources Customer Service